Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis. “Given their leadership in cell therapy ...